指南与共识肺栓塞与肺血管病

2015年欧洲肺高压指南风险分层模型对肺动脉高压死亡率的预测验证

Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model.
指南 / 共识 · Eur Respir J · 2017-08-03

该研究基于COMPERA登记中1588例新诊断肺动脉高压患者,验证2015年欧洲肺高压指南风险分层策略的死亡率预测效能。结果显示低、中、高危组1年死亡率分别为2.8%、9.9%和21.2%,组间差异显著(p<0.001),且在随访和主要亚组中均有效。

要点

  • 低危组1年死亡率2.8%,中危组9.9%,高危组21.2%。
  • 三组间死亡率差异均显著(p<0.001)。
  • 简化版风险分层策略在随访和主要亚组中均有效。

核心结论

  • 2015年欧洲肺高压指南提出的简化版风险分层策略可准确预测肺动脉高压患者的死亡率。

研究设计与样本

  • 基于COMPERA欧洲肺高压登记的前瞻性队列分析,纳入1588例新诊断肺动脉高压患者。

主要发现

  • 低危组(n=196)1年死亡率为2.8%,中危组(n=1116)为9.9%,高危组(n=276)为21.2%。
  • 三组间死亡率差异均显著(p<0.001)。
  • 风险分层策略在随访和主要肺动脉高压亚组中均显示有效。

关键数值与推荐

  • 低危:估计1年死亡率<5%;中危:5-10%;高危:>10%。
  • 简化版评估变量包括WHO功能分级、6分钟步行距离、BNP或NT-proBNP、右心房压、心指数和混合静脉血氧饱和度。

临床怎么用

  • 临床可采用该简化版风险分层模型对新诊断肺动脉高压患者进行死亡风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 2015 European pulmonary hypertension (PH) guidelines propose a risk stratification strategy for patients with pulmonary arterial hypertension (PAH). Low-, intermediate- and high-risk strata are defined by estimated 1-year mortality risks of <5%, 5-10% and >10%, respectively. This risk assessment strategy awaits validation.We analysed data from patients with newly diagnosed PAH enrolled into COMPERA (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension), a European-based PH registry. An abbreviated version of the risk assessment strategy proposed by the European PH guidelines was applied, using the following variables: World Health Organization functional class, 6-min walking distance, brain natriuretic peptide or its N-terminal fragment, right atrial pressure, cardiac index and mixed venous oxygen saturation.Data from 1588 patients were analysed. Mortality rates were significantly different between the three risk strata (p<0.001 for all comparisons). In the entire patient population, the observed mortality rates 1 year after diagnosis were 2.8% in the low-risk cohort (n=196), 9.9% in the intermediate-risk cohort (n=1116) and 21.2% in the high-risk cohort (n=276). In addition, the risk assessment strategy proved valid at follow-up and in major PAH subgroups.An abbreviated version of the risk assessment strategy proposed by the current European PH guidelines provides accurate mortality estimates in patients with PAH.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017. PMID: 28775047. doi:10.1183/13993003.00740-2017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。